Elevation of CD4+ differentiated memory T cells is associated with acute cellular and antibody-mediated rejection after liver transplantation

Transplantation

Volumn 95, Issue 12, 2013, Pages 1512-1520

  Gerlach, Undine A ^a   Vogt, Katrin ^a   Schlickeiser, Stephan ^a   Meisel, Christian ^a   Streitz, Mathias ^a   Kunkel, Desiree ^a   Appelt, Christine ^a   Ahrlich, Stefanie ^a   Lachmann, Nils ^a   Neuhaus, Peter ^a   Pascher, Andreas ^a   Sawitzki, Birgit ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute cellular rejection; Acute humoral rejection; Liver transplant; Memory T cells

Indexed keywords

BASILIXIMAB; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALCOHOL LIVER CIRRHOSIS; ANTIBODY MEDIATED REJECTION; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; EFFECTOR CELL; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TERMINAL DIFFERENTIATED EFFECTOR MEMMORY T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84880136711     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318290de18     Document Type: Article

References (42)

1. + T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009; 9: 179.
2. Ho J, Wiebe C, Gibson IW, et al. Immune monitoring of kidney al-lografts. Am J Kidney Dis 2012; 60: 629.
3. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500.
4. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428.
5. Schmeding M, Sauer IM, Kiessling A, et al. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 2007; 12: 15.
6. O'Grady J. The immunoreactive patient: rejection and autoimmune disease. Liver Transplant 2011; 17: S29.
7. Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transplant Immunol 2012; 26: 62.
8. Kamar N, Lavayssiere L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426.
9. Schadde E, d'Alessandro AM, Musat AI, et al. Donor-specific HLA-antibody-mediated humoral rejection in a liver transplant recipient fully reversed with plasmapheresis and immunoglobulin. Clin Transplant 2006; 20: 479.
10. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022.
11. Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115: 3146.
12. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971.
13. Brehm MA, Daniels KA, Priyadharshini B, et al. Allografts stimulate cross-reactive virus-specific memory CD8 T cells with private specificity. Am J Transplant 2010; 10: 1738.
14. D'Orsogna LJ, Roelen DL, Doxiadis, II, et al. Alloreactivity from human viral specific memory T-cells. Transplant Immunol 2010; 23: 149.
15. Nather BJ, Nickel P, Bold G, et al. Modified ELISPOT techniqueV highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transplant Immunol 2006; 16: 232.
16. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78: 1640.
17. Pascher A, Proesch S, Pratschke J, et al. Rat cytomegalovirus infection interferes with anti-CD4 mAb-(RIB 5/2) mediated tolerance and induces chronic allograft damage. Am J Transplant 2006; 6: 2035.
18. Poggio ED, Augustine JJ, Clemente M, et al. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847.
19. van de Berg PJ, Yong SL, et al. Characteristics of alloreactive T cells measured before renal transplantation. Clin Exp Immunol 2012; 168: 241.
20. + T cell subpopulation and its relation to outcome. Liver Transplant 2006; 12: 792.
21. + TEMRA cells are associated with the risk for acute kidney al-lograft rejection. Transplantation 2012; 94: 63.
22. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003; 101: 4260.
23. Hidalgo LG, Einecke G, Allanach K, et al. The transcriptome of human cytotoxic T cells: similarities and disparities among allostimulated CD4(+) CTL, CD8(+) CTL and NK cells. Am J Transplant 2008; 8: 627.
24. Hidalgo LG, Einecke G, Allanach K, et al. The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant 2008; 8: 637.
25. Macedo C, Walters JT, Orkis EA, et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation 2012; 93: 813.
26. + T cell-mediated antimicrobial activity against Myco-bacterium tuberculosis in humans. J Clin Invest 2009; 119: 1167.
27. Joshi NS, Kaech SM. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol 2008; 180: 1309.
28. Valujskikh A, Li XC. Memory T cells and their exhaustive differentiation in allograft tolerance and rejection. Curr Opin Organ Transplant 2012; 17: 15.
29. Siepert A, Ahrlich S, Vogt K, et al. Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. Am J Transplant 2012; 12: 2384.
30. Abadja F, Alamartine E, Berthoux F, et al. Quantification of circulating regulatory T cells by flow cytometry in kidney transplant patients after basiliximab induction therapy. Transplantation 2010; 89: 366.
31. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.
32. Cherukuri A, Salama AD, Carter C, et al. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. Am J Transplant 2012; 12: 919.
33. Vondran FW, Timrott K, Tross J, et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl Int 2010; 23: 514.
34. Cherkassky L, Lanning M, Lalli PN, et al. Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker. Am J Transplant 2011; 11: 1388Y1396.
35. Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transplant 2004; 10: 728.
36. Lupo L, Panzera P, Tandoi F, et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 2008; 86: 925.
37. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplant 2002; 8: 132.
38. Wang XF, Li JD, Peng Y, et al. Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials. Transplant Proc 2010; 42: 4567.
39. Demetrias AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658Y663.
40. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526.
41. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
42. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848.